These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28375406)

  • 1. Hot Topics in Primary Care: Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP.
    Flamm SL
    J Fam Pract; 2017 Apr; 66(4 Suppl):S34-S39. PubMed ID: 28375406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
    Younossi ZM
    Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic encephalopathy: suspect it early in patients with cirrhosis.
    Wakim-Fleming J
    Cleve Clin J Med; 2011 Sep; 78(9):597-605. PubMed ID: 21885692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pay more attention to hepatic encephalopathy].
    Labenz J
    MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
    MMW Fortschr Med; 2000 Jun; 142(25):56-7. PubMed ID: 10920673
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    Anastasopoulos NT; Lianos GD; Tatsi V; Karampa A; Goussia A; Glantzounis GK
    Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1025-1033. PubMed ID: 32746645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PROs and cons of crystalline lactulose for suspected covert HE among patients with cirrhosis and activity impairment: Are we using the right assessments?
    Jesudian AB; Fortune BE
    Hepatology; 2023 Oct; 78(4):1015-1016. PubMed ID: 37246443
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving the identification and monitoring of cirrhosis.
    Keane MG; Hensher C; Pereira SP
    Practitioner; 2016 Nov; 260(1798):25-9. PubMed ID: 28968053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Confusing Picture: Refractory Encephalopathy Complicating Nonalcoholic Steatohepatitis.
    Kravetz JD; Varma P; Hosseini R; Thomas A; Eder MD
    Am J Med; 2020 Oct; 133(10):e546-e548. PubMed ID: 32087105
    [No Abstract]   [Full Text] [Related]  

  • 18. [Research advances in diagnosis of non-alcoholic fatty liver disease].
    Wang JH; Yu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.